LIN28B Antibody, FITC conjugated - Cat. #: CSB-PA741049LC01HU

SKU: CSB-PA741049LC01HU

Size :50ug

Clone Number:

Aliases:CSDD 2 antibody; CSDD2 antibody; FLJ16517 antibody; Lin 28 homolog B (C. elegans) antibody; Lin 28.2 antibody; Lin-28B antibody; LIN28B antibody; LN28B_HUMAN antibody; Protein lin-28 homolog B antibody

Product Type:Polyclonal Antibody

Immunogen Species:Homo sapiens (Human)

UniProt ID:Q6ZN17

Immunogen:Recombinant Human Protein lin-28 homolog B protein (166-250AA)

Raised in:Rabbit

Species Reactivity:Human

Tested Applications:

Background:Suppressor of microRNA (miRNA) biogenesis, including that of let-7 and possibly of miR107, miR-143 and miR-200c. Binds primary let-7 transcripts (pri-let-7), including pri-let-7g and pri-let-7a-1, and sequester them in the nucleolus, away from the microprocessor complex, hence preventing their processing into mature miRNA (PubMed:22118463). Does not act on pri-miR21 (PubMed:22118463). The repression of let-7 expression is required for normal development and contributes to maintain the pluripotent state of embryonic stem cells by preventing let-7-mediated differentiation. When overexpressed, recruits ZCCHC11/TUT4 uridylyltransferase to pre-let-7 transcripts, leading to their terminal uridylation and degradation (PubMed:19703396). This activity might not be relevant in vivo, as LIN28B-mediated inhibition of let-7 miRNA maturation appears to be ZCCHC11-independent (PubMed:22118463). Interaction with target pre-miRNAs occurs via an 5\'-GGAG-3\' motif in the pre-miRNA terminal loop. Mediates MYC-induced let-7 repression (By similarity). When overexpressed, isoform 1 stimulates growth of the breast adenocarcinoma cell line MCF-7. Isoform 2 has no effect on cell growth.

Clonality:Polyclonal

Isotype:IgG

Purification Method:>95%, Protein G purified

Conjugate:FITC

Buffer:Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4

Form:Liquid

Stroage:Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Target Names:LIN28B

Research Areas:Epigenetics and Nuclear Signaling; Cancer